Andhrapradesh Journal

Advanced Renal Cell Carcinoma Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Advanced Renal Cell Carcinoma Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

March 23
15:47 2020
Advanced Renal Cell Carcinoma Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

DelveInsight has launched a new report on Advanced Renal Cell Carcinoma (RCC) Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Advanced Renal Cell Carcinoma (RCC) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Advanced Renal Cell Carcinoma (RCC), historical and forecasted epidemiology as well as the Advanced Renal Cell Carcinoma (RCC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Advanced Renal Cell Carcinoma (RCC) market report provides current treatment practices, emerging drugs, Advanced Renal Cell Carcinoma (RCC) market share of the individual therapies, current and forecasted Advanced Renal Cell Carcinoma (RCC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Advanced Renal Cell Carcinoma (RCC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Renal Cell Carcinoma (RCC), also known as kidney cancer, hypernephroma or renal adenocarcinoma or the Grawitz tumor, is the most common type of kidney cancer, accounting for 85% of primary renal malignancies in adults. It is a disease in which malignant (cancer) cells are found in the lining of tubules in the kidney. RCC is a fast-growing cancer and often spreads to the lungs and surrounding organs. It varies from Stage I with tumor confined to kidney tissues to Stage IV with tumor spread to different organs. The stage IV condition of tumor leads to the metastatic or advanced stage of renal cell carcinoma. 

 

Request for :- Advanced Renal Cell Carcinoma free sample page

 

RCC Epidemiology

The Advanced Renal Cell Carcinoma (RCC) epidemiology division provide insights about historical and current Advanced Renal Cell Carcinoma (RCC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Report Key facts:- 

1. According to a study conducted by Garfield et al. titled “Cancer, Renal Cell,” globally, the incidence of RCC varies, with the highest rates observed in the Czech Republic and North America. In the United States, there are approximately 63,000 new cases and almost 14,000 deaths each year. RCC is the most common type of kidney cancer in adults. It occurs most often in men ages 50 to 70.

2. A study conducted by Saad et al. titled “Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2Decades: A SEER-Based Study” stated that in the United States, the estimated number of diagnosed cases in 2018 is 65,340 and the estimated number of deaths is 14,970. The overall RCC incidence during the study period was 11.281 per 100,000 person-year.

3. Pal et al. conducted a study titled “Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database” wherein approximately 65% of patients with newly diagnosed RCC have localized disease at the time of diagnosis, while 25 to 30% have advanced or metastatic disease; approximately 20 to 40% of patients with localized RCC will progress to metastatic RCC (mRCC

 

According to the study conducted by Wu et al. titled “Epidemiology of Renal Cell Carcinoma,” the incidence of kidney cancer ranks 9th and 14th among all cancers diagnosed in men and women worldwide, respectively. The age-adjusted incidence rate is 6 per 100,000 in males and 3 per 100,000 in females. In the United States, kidney cancer is the sixth most common cancer in men and eighth most common in women, with an estimated 63,920 new cases and 13,860deaths in 2014. Renal cell carcinoma (RCC) accounts for more than 85 % of all kidney cancers with the remainder being renal pelvis carcinoma (approximately 10 %) and other rare malignancies.

 

Key companies working on RCC that are given below-

1. Genentech Pharma Co. 

2. Pfizer Pharma Co. 

 

Name of drugs covered are given below:- 

1. Bevacizumab

2. Axitinib

 

Table of Contents

1. Key Insights

2. Executive Summary of Advanced Renal Cell Carcinoma (RCC)

3. Competitive Intelligence Analysis for Advanced Renal Cell Carcinoma (RCC)

4. Advanced Renal Cell Carcinoma (RCC) : Market Overview at a Glance

4.1. Advanced Renal Cell Carcinoma (RCC) Total Market Share (%) Distribution in 2017

4.2. Advanced Renal Cell Carcinoma (RCC) Total Market Share (%) Distribution in 2030

5. Advanced Renal Cell Carcinoma (RCC) : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Advanced Renal Cell Carcinoma (RCC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Advanced Renal Cell Carcinoma (RCC) Treatment and Management

8.2. Advanced Renal Cell Carcinoma (RCC) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Advanced Renal Cell Carcinoma (RCC) Treatment

11. Marketed Products

12. Emerging Therapies

13. Advanced Renal Cell Carcinoma (RCC) : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Advanced Renal Cell Carcinoma (RCC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Why should you buy this report ?

  • The report will help in developing business strategies by understanding trends shaping and driving the Advanced Renal Cell Carcinoma (RCC) market
  • To understand the future market competition in the Advanced Renal Cell Carcinoma (RCC) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Advanced Renal Cell Carcinoma (RCC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Advanced Renal Cell Carcinoma (RCC) market
  • To understand the future market competition in the Advanced Renal Cell Carcinoma (RCC) market

Related Reports:-

1. Advanced liver cancer – Pipeline Insights, 2020

2. Advanced Pancreatic Cancer – Pipeline Insights, 2020

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles